VistaGen Therapeutics Inc. (Nasdaq: VTGN) to Ring The Nasdaq Stock Market Closing Bell
March 10 2017 - 3:17PM
What:VistaGen Therapeutics Inc. (Nasdaq:VTGN),
a clinical-stage biopharmaceutical company focused on developing
new generation medicines for depression and other central nervous
system (CNS) disorders, will visit the Nasdaq MarketSite in Times
Square.
In honor of the occasion, Shawn K. Singh, CEO &
Director, will ring the Closing Bell.
Where:Nasdaq MarketSite – 4 Times Square – 43rd
& Broadway – Broadcast Studio
When:Monday, March 13, 2017 – 3:45 p.m. to 4:00
p.m. ET
VistaGen Contact:Mark A. McPartland(650)
577-3600IR@vistagen.com
Nasdaq MarketSite:Emily Pan(646)
441-5120emily.pan@nasdaq.com
Feed Information:Fiber Line (Encompass
Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC
3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media:For multimedia features such as
exclusive content, photo postings, status updates and video of bell
ceremonies, please visit our Facebook
page:http://www.facebook.com/NASDAQ.
For photos from ceremonies and events, please visit our
Instagram page:http://instagram.com/nasdaq
For livestream of ceremonies and events, please visit our
YouTube page:http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter
page:http://twitter.com/nasdaq
For exciting viral content and ceremony photos, please visit our
Tumblr page:http://nasdaq.tumblr.com/
Webcast: A live stream of the Nasdaq Closing
Bell will be available at: https://new.livestream.com/nasdaq/live
or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos: To obtain a hi-resolution photograph of
the Market Close, please go to
http://business.nasdaq.com/discover/market-bell-ceremonies and
click on the market close of your choice.
About VistaGenVistaGen Therapeutics,
Inc. (NASDAQ:VTGN), is a clinical-stage biopharmaceutical
company focused on developing new generation medicines for
depression and other central nervous system (CNS) disorders.
VistaGen's lead CNS product candidate, AV-101, is a new generation
oral antidepressant drug candidate in Phase 2 development. AV-101's
mechanism of action is fundamentally differentiated from all
FDA-approved antidepressants and atypical antipsychotics used
adjunctively to treat MDD, with potential to drive a paradigm shift
towards a new generation of safer and faster-acting
antidepressants. AV-101 is currently being evaluated by the U.S.
National Institute of Mental Health (NIMH) in a Phase 2a
monotherapy study in MDD being fully funded by the NIMH and
conducted by Dr. Carlos Zarate Jr., Chief, Section on the
Neurobiology and Treatment of Mood Disorders and Chief of
Experimental Therapeutics and Pathophysiology Branch at the NIMH.
VistaGen is preparing to launch a 280-patient Phase 2b study of
AV-101 as an adjunctive treatment for MDD patients with inadequate
response to standard, FDA-approved antidepressant therapies. Dr.
Maurizio Fava of Harvard University will be the Principal
Investigator of the Phase 2b study. AV-101 may also have the
potential to treat multiple CNS disorders and neurodegenerative
diseases in addition to MDD, including chronic neuropathic pain,
epilepsy, Parkinson's disease and Huntington's disease, where
modulation of the NMDAR, AMPA pathway and/or key active metabolites
of AV-101 may achieve therapeutic benefit.
VistaStem Therapeutics is VistaGen's wholly owned subsidiary
focused on applying human pluripotent stem
cell (hPSC) technology, internally and with third-party
collaborators, to discover, rescue, develop and commercialize
proprietary new chemical entities (NCEs), including small
molecule NCEs with regenerative potential, for CNS and other
diseases, and cellular therapies involving stem cell-derived blood,
cartilage, heart and liver cells. In December 2016, VistaGen
exclusively sublicensed to BlueRock Therapeutics LP, a next
generation regenerative medicine company established by Bayer AG
and Versant Ventures, rights to certain proprietary technologies
relating to the production of cardiac stem cells for the treatment
of heart disease.
For more information, please
visit www.vistagen.com and connect with VistaGen
on Twitter, LinkedIn and Facebook.
About NasdaqNasdaq (Nasdaq:NDAQ) is a leading
provider of trading, clearing, exchange technology, listing,
information and public company services across six continents.
Through its diverse portfolio of solutions, Nasdaq enables clients
to plan, optimize and execute their business vision with
confidence, using proven technologies that provide transparency and
insight for navigating today's global capital markets. As the
creator of the world's first electronic stock market, its
technology powers more than 85 marketplaces in 50 countries, and 1
in 10 of the world's securities transactions. Nasdaq is home to
approximately 3,800 listed companies with a market value of $10.1
trillion and nearly 18,000 corporate clients. To learn more, visit:
business.nasdaq.com.
-NDAQA-
Vistagen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vistagen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Sep 2023 to Sep 2024